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ABSTRACT
This invention relates to cisplatin type fluorescently
labeled compounds. In particular, the compounds are
bis (5-aminofluorescein)-dichloroplatinum (II) or certain substituted analogues thereof. The compounds are
useful as radiation sensitivity enhancers and as fluorescent biological tracers. The invention also relates to a
unique, single step synthesis for preparing said compounds.
4 Claims, 3 Drawing Figures
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LOW TOXICITY RADIATION SENSITIZER
CROSS REFERENCE TO RELATED
APPLICATION
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This application is a division of application Ser. No.
440,840, filed Nov. 12, 1982 now U.S. Pat. No.
4,490,543 issued Dec. 25, 1984.
BACKGROUND OF THE INVENTION

10

In addition to being used in cancer chemotherapy,
cisplatin is also known as a radiation sensitizer. That is,
such that the cisplatin enhances the effect of ionizing
radiation on malignant tumors in order to improve local
and regional cancer treatment by radiation, see, for 15
example, Overgaard, et al., Cancer Treatment Reports
Vol. 65, Nos. 5-6, May/June, 1981, p. 501-503, which is
incorporated herein by reference. There, it is reported
that cisplatin will enhance the radiation response in
tumors by a factor of between 1.2 and 1.7 time the effec- 20
tiveness if no cisplatin is used. The report goes on to
describe the use of cisplatin as a marked and selective
enhancement of radiation's effects in solid tumors. Cisplatin has the formula:
25
Cl

"

NH3

Pt /

Cl /

"

NH3

30
The chemical name for cisplatin is cis-diaminedichloroplatinum(II). It is a square planar molecule and its effectiveness in biological systems is believed to be related to
its configuration. The compound was recognized for its
biological significance in the 1960's and its radiation
sensitizing properties were demonstrated in the midl 970's.
While cisplatin per se has been known as an effective
radiation sensitizer, it does have problems which have
inhibited its practical use. The primary problem is its
high level of toxicity to normal living cells. Thus, while
it may successfully sensitize a carcinoma, making it
highly susceptible to radiation treatment, it also is quite
toxic to the surrounding normal cells. There is, therefore, a real and continuing need to develop a radiation
sensitizer which is at least equally as effective as cisplatin with respect to the enhancement of sensitivity of
carcinomas to radiation, but which will allow such
sensitization without being toxic to surrounding normal
living cells.
Needless to say, if one could develop a radiation
sensitizer of high level sensitizing effect, but with minimal toxicity to surrounding normal living cells, the net
effect would be that smaller doses of radiation could be
used to give the effect now achieved with only larger
radiation doses and thus, the total body exposure to
radiation reduced. Alternatively, for a given radiation
dose, its effectiveness could be increased without fear of
causing high level toxicity to surrounding normal tissue
cells.
It is a primary objective of the present invention to
provide a radiation sensitizer which is at least equal to
cisplatin in selective enhancement of radiation response,
but which provides such radiation response with a
much, much lower toxicity level to normal live cells.
An additional objective of the present invention is to
provide a radiation sensitizer which is at least equal to
cisplatin in enhancement of radiation response, but
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which is several times less toxic than cisplatin to normal
living cells.
A further objective of this invention is to provide a
radiation sensitizer which is at least equal to cisplatin in
radiation sensitization effect, but which is estimated to
be up to ten times less toxic to normal cells.
Another object is to provide a compound which like
cisplatin itself has antineoplastic properties.
A still further objective of the present invention is to
provide a molecufar tracer which is fluorescent, thus
providing a unique and highly effective biological
tracer which is capable of binding to DNA nucleotides,
proteins, and lipids.
Yet another objective of this invention is to provide a
fluorescent biological tracer which also will function as
an effective biological stain for use in electron microscopy and fluorescence microscopy.
Still another objective of the present invention is to
provide a radiation sensitizer that has stability and solubility properties which make the compounds easy to
administer in dosage quantity.
And another objective of the present invention is to
provide a radiation sensitizer which is soluble in water
and soluble in common universal solvents such as dimethylsulfoxide, methyl alcohol, ethyl alcohol, acetone, etc.
Another very important objective of the present invention is to provide a highly effective, single step synthesis for production of fluorescently labeled cisplatin
type compounds, which do not employ cisplatin at all in
the synthesis procedure, but instead employ readily
available compounds in a single step, direct combination synthesis.
TM method and manner of accomplishing each of the
above objectives, as well as others, will become apparent from the detailed description of the invention which
follows hereinafter.
SUMMARY OF THE INVENTION

This invention relates to cisplatin type fluorescently
labeled compounds which are effective radiation sensitizers. In particular, the compounds are bis(5-amino45 fluorescein)dichloroplatinum(II) (abbreviated cis-CFP)
or certain substituted analogs thereof. They are equal to
cisplatin from the standpoint of their radiation sensitivity enhancement, but are up to ten times less toxic to
normal living cells than cisplatin. In addition, the com50 pounds are highly effective, fluorescent biological tracers. The invention also relates to a unique, single step
synthesis for preparing fluorescently labeled cisplatin
type compounds, without ever employing cisplatin in
the synthesis route. As a result, the synthesis involves a
55 platinum salt and a relatively non-toxic 5-aminofluorescein, which are readily available.
BRIEF DESCRIPTION OF THE DRAWINGS
60

65

The drawings are graphs illustrating the good radiation sensitizing properties of the compounds of this
invention, coupled with their low toxicity level compared to cisplatin.
DETAILED DESCRIPTION OF THE
INVENTION
The compounds of this invention have the following
formula:
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wherein "X" is a halide and Rand R' are selected from
the group consisting of hydrogen, C1 to C12 alkyl, C1 to
C12 alkenyl, C1 to C12 alkynyl, and aryl. Preferably "X"
is a chloride or bromide, and most preferably chloride.
It is preferred that Rand R' be selected from the group
consisting of C1 to C6 alkyl, alkenyl, alkynyl, and aryl.
Most preferably, both R and R' are hydrogen.
The very most preferred compound of the invention
is bis(5-aminofluorescein)dichloroplatinum(II).
The compounds of the present invention can be
thought of as fluorescein derivatives of cisplatin.
Cisplatin has been known for several decades but has
only become biologically important since about the
mid-1960's. It is a square planar molecule known to
have adverse properties to normal, but especially to
neoplastic cells. It is also known as an effective radiation sensitizer. The term "radiation sensitizer" refers to
enhancement of the effect of ionizing radiation on cells,
most typically malignant cells in order to improve local
and regional cancer treatments. Cisplatin selectively
sensitizers and enhances the effective radiation response
in malignant growths with a lesser effect in normal
tissues. Thus, cisplatin has been accorded some high
level interest, because of its potential use in chemother·. apy. However, one primary disadvantage with cisplatin
is that it has a high level of toxicity to normal tissue
cells.
Surprisingly, and contrary to the expectations in
working with cisplatin per se, the fluorescein derivatives of this invention are equal to cisplatin as radiation
sensitizers, but, contrary to cisplatin, have a very low
level toxicity to surrounding tissue cells. In fact, data
developed to date, reveal a toxicity level up to as much
as ten times lower than cispiatin. As a result, the compounds of this invention, and particularly the most preferred compound bis(5-aminofluorescein)dichloroplatinum(II), can be used as a much more effective
radiation sensitizer than cisplatin. In particular, since
the aminofluorescein derivative has a low toxicity level,
larger quantities can be used in dosage treatments. As a
result, successful radiation treatments can occur with
much smaller radiation doses, resulting in overall reduced body exposure to radiation. Then too, large doses
of the radiation sensitizer can be used, increasing the
radiation sensitization effect, without any significant
worry of the high level toxicity to normal cells. In
particular, toxicity levels of the most preferred compound of this invention are up to ten times less than
cisplatin.
The compounds of the present invention are also
useful as biological tracers, since they are both fluorescent and have high binding capabilities to nucleic acids,
proteins and lipids. Prior to the development of the
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compounds of this invention, it is not believed that there
has been a biological tracer which is both fluorescent
and also offers binding properties similar to that of
cisplatin in that it may bind to nucleic acids, proteins
and lipids, and thus be easily traceable. This fluorescent
property, coupled with the binding ability to biologically important compounds, allows for fluorescent labeling of cells in biological work.
While the compounds discussed have been referred
to as platinum compounds, it is possible that other compounds can be made employing as the metal atom, any
of the metals of the platinum metal series, that is, rubidium, rhodium, palladium, osmium, irridium, and platinum. It is therefore contemplated as still within the
scope of this invention if the central metal atom of the
platinum compounds is replaced with other of the referred to metals of the platinum metal series.
Another highly important feature and advantage of
the compounds of the present invention is that they
have stability and solubility characteristics which make
them easy to work with from the standpoint of dosage
units. That is to say, they are soluble in water, they are
relatively stable, and they will dissolve in many universally employed solvents such as dimethylsulfoxide,
methanol, ethanol and acetone.
A surprisingly simple and straightforward single step
reaction synthesis has been developed for producing the
compounds of this invention. The method is surprising
because one would normally except cisplatin per se to
be the starting material, since the compounds are derivatives of cisplatin. However, cisplatin is not involved in
the reaction at all. And yet, the compound which is
produced has all of the r~diation sensitivity properties
of cisplatin. In accordance with the process of this invention, 5-aminofluorescein (Isomer I), or a substituted
5-aminofluorescein, is reacted with an alkali metal tetrachloroplatinate(II) in a single step, direct combination
synthesis. 5-aminofluorescein (Isomer I) has the formula:

45

50
HO

The alkali metal tetrachloroplatinate(II) is preferably
55 potassium tetrachloroplatinate(II) of the formula
K1[PtCl4]. In the preferred methodology, an aqueous
solution of potassium tetrachloroplatinate(II) is mixed
with a hot methanol solution of 5-aminofluorescein,
with the molar ratio of potassium tetrachloro60
platinate(II) to 5-aminofluorescein being 1:2. The solutions are mixed and the mixture is heated (with evaporation) at a slightly elevated temperature, perhaps 60° C.
After cooling to room temperature, a brown precipitate
65 forms which can be separated and recrystallized.
The following examples are offered to further illustrate, but not limit, the invention. It is understood that
modifications may be made in the illustrated examples.
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EXAMPLES
Preparation of bis(5-aminofluorescein)dichloroplatinum(II) was accomplished using direct combination of an aqueous solution of potassium tetrachloroplatinate(II) and 5-aminofluorescein. In particular 0.415
grams of K1[PtCl4] in 25 milliliters of water was added
to 0.694 grams of 5-aminofluorescein in 50 milliliters of
boiling methanol. They were mixed, and the solution
was kept at about 60° C. for one hour. Thereafter, it was
allowed to cool, at which point a brown precipitate was
observed. The precipitating compound was filtered,
washing a little with absolute ethanol, and then with
diethyl ether. The brown compound remained. It
weighed 0.4 grams.
The reaction process was run again, exactly as described above, and gave a brown solid of 0.5 grams.
Nuclear magnetics resonance (NMR) testing, infrared (IR) analysis, visible-UV spectroscopy, and quantitative, elemental analysis all confirmed the presence of
bis(5-aminofluorescein)dichloroplatinum(II). In these
runs, the starting platinum compound came from the
Alpha Division of Ventron Corporation, and the starting 5-aminofluorescein compound came from Sigma
Chemical in St. Louis, Mo. Of course, other convenient
and suitable sources for the starting materials may be
utilized.
Numerous repetitions of the synthesis procedure
shown here, have occurred and all upon various analysis techniques mentioned herein confirm the presence of
bis 5-aminofluorescein)dichloroplatinum(II).
The process was repeated using as the starting material K1[PtBr4] and the resulting product was bis(5aminofluorescein)dibromoplatinum(II).
The bis(5-aminofluorescein)dichloroplatinum(II) prepared in the manner previously described herein, was
tested for effectiveness as a radiation sensitizer. In particular, the compound was complexed with nucleotides
in vitro. The stability of the compound was studied in a
buffered saline solution over a period of time. Finally,
the cell growth effects of the compound from the standpoint of its effects on living cells were studied, as described below.
The drawings illustrate the effective nature of the
compounds of this invention as radiation sensitizers, and
compare the toxicity level of the compounds of this
invention with the toxicity level of cisplatin from the
standpoint of their effects on living cells.
FIG. 1 shows the effectiveness of the compound of
this invention, in particular bis(5-aminofluorescein)dichloroplatinum(II) in terms of its effectiveness as a
radiation sensitizer. In particular, in looking at FIG. 1,
the "x" axis shows radiation dose as measured in kilorads (krad). The "y" axis shows the surviving fraction
of bacterial cells (S. typhimurium Tm 677). The line
represented by black dots and dashes shows the effect of
radiation alone on this bacterial system under a nitrogen
blanket. This simulates anaerobic conditions in vivo.
The lines showing squares with dashes and pulses with
dashes shows the decrease in survival produced by 20
um and 100 um cis-CFP respectively over a range of
radiation dosages. The radiosensitization produced by
cis-CFP exhibits a dose dependent effect. It also exhibits
a much reduced toxicity as compared to equamolar
concentrations of cisplatin; this makes it difficult to
make direct comparisons. Studies using the S. typhimurium Tm 677 bacterial system produce the following
data.
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Concentration of
Compound

Toxicity after
~ hour at room
temperature
[no radiation
survival]

IOOuM
IOOuM

100% survival

10%

Radiation
Enhancement
Ratio
2.4
1.6

Even though the enhancement of the 100 uM concentration is less for cis-CFP than for displatin, the extreme
differences in toxicity demonstrate the utility of cisCFP as compared to cisplatin.
Though difficult to compare directly, other work
using mice to study cisplatin-induced radiosensitization
shows a radiation enhancement ratio of up to 1. 7. This
is comparable to the 1.6 value demonstrated for cis-CFP
in the bacterial system.
Also, cisplatin under nitrogen is an assay using E. coli
exposed to 5 X IQ-5M cisplatin shows an enhancement
ratio of about 1.77. It therefore can be seen that although direct comparision is difficult, they are comparable in radiation sensitizing ability.
FIG. 2 shows the growth of a culture of Tetrahymena in a nutrient medium which comprises 2% by
weight of proteose peptone, 0.1 % by weight sodium
hydrogen phosphate, 0.1 % sodium acetate and with the
balance being distilled water. The "x" axis shows culture growth in time with the "y" axis indicating media
density, an indication of cell numbers. As can be seen,
the greatest cell growth is exhibited in the control,
which are free living and growing protozoan cells in the
presence of a nutrient. The toxicity of cisplatin when
added to the control solution at a concentration of IQ-5
molar is also shown. The toxicity of the compounds of
this invention at IQ-4 molar and IQ-5 molar concentrations are likewise shown. It can be seen that the level of
toxicity compounds of the present invention is much,
much less at a given molar concentration than is cisplatin. This is further illustrated in FIG. 3, which shows
the same free living protozoan cell Tetrahymena, but
shows the motility rate declining in the presence of
cisplatin and a compound of the invention. Cisplatin is
the dotted line and the compound of the invention is the
solid line. There, the "x" axis measures time of exposure
with the "y" axis measuring the motility rate of the
organisms. The steeper the line indicating the mobility
of the organism, the more toxic the compound. There,
the concentration in both instances of cisplatin and the
compound of the invention was 2 X IQ-3 molar. It can
be seen that at any given time, the mobility is much
more reduced by cisplatin than the compound of this
invention, indicating a much higher toxicity level of
cisplatin.
It therefore can be seen that the compounds of the
present invention are substantially equal in radiation
sensitizing effect to cisplatin, but that they are up to as
many as ten times less toxic to normal living cells, see
FIGS. 2 and 3 and the data presented therein.
Thus, the invention accomplishes at least all of its
stated objectives.
What is claimed is:
1. A method of increasing the radiation sensitivity of
living cells comprising:
administering to an animal a small radiation sensitizing effective amount of a compound of the formula
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where Xis a halide.
2. The method of claim 1 wherein Xis chloride.
3. The method of claim 1 wherein X is bromide.
4. The method of claim 1 wherein the amount of said
compound administered is from about 20 micromoles to
about 100 micromoles.
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